Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

590P - Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study


10 Sep 2022


Poster session 09


Valentina Tuninetti


Annals of Oncology (2022) 33 (suppl_7): S235-S282. 10.1016/annonc/annonc1054


V. Tuninetti1, E. Ghisoni2, S. Pignata3, E. Picardo4, F. Raspagliesi5, C. Andreetta6, E. Maldi7, G. Artioli8, S. Mammoliti9, M. Roccio10, A. Sikokis11, N. Biglia12, A. Parisi13, V.D. Mandato14, C. Carella15, G. Cormio16, M. Marinaccio17, G. Scotto1, M. Di Maio1, G. Valabrega1

Author affiliations

  • 1 Department Of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 - Turin/IT
  • 2 Immuno-oncology Service, Department Of Oncology, Lausanne University Hospital; Ludwig Institute for Cancer Research, Lausanne/CH
  • 3 Dipartimento Uro-ginecologico, Istituto Nazionale Tumori di Napoli IRCCS, Fondazione G Pascale, Naples/IT
  • 4 Department Of Obstetrics And Gynaecology, University Of Torino, Torino, Italy, Ospedale Sant'Anna di Torino, 10126 - Torino/IT
  • 5 Gynecologic Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 6 Department Of Oncology, Santa Maria Della Misericordia University Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 - Udine/IT
  • 7 Pathology Dept., IRCCS - Istituto di Candiolo - FPO, 10060 - Candiolo/IT
  • 8 Medical Oncology Department, ULSS 2 UOC Oncologia Manca Trevigiana, 30035 - Mirano/IT
  • 9 Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 10 Department Of Obstetrics And Gynecology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, 27100 - Pavia/IT
  • 11 Oncology, Ospedal Maggiore di Parma, 43126 - Parma/IT
  • 12 Obstetrics And Gynaecology Unit, Department Of Surgical Sciences, School Of Medicine, University of Turin, Ordine Mauriziano Hospital, 10128 - Turin/IT
  • 13 Department Of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila/IT
  • 14 Unit Of Obstetrics And Gynaecology, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Reggio Emilia/IT
  • 15 Gynecologic Oncology Unit, Istituto Tumori Giovanni Paolo II, 70124 - Bari/IT
  • 16 Gynecologic Oncology Unit, Policlinico di Bari - Ospedale Giovanni XXIII, 70124 - Bari/IT
  • 17 Interdisciplinar Department Of Medicine, Policlinico di Bari - Ospedale Giovanni XXIII, 70124 - Bari/IT

Abstract 590P


Best predictor of response to PARP inhibitors (PARPi) in ovarian cancers (OC) is the presence of BRCA1 or BRCA2 mutations. However, also OC carrying other homologous recombination deficiency (HRD) can benefit from PARPi. HRD definition is still not standardized and no test is available to discriminate among BRCA wild type (WT) patients (pts) those who will benefit from PARPi. Since high Ki67 predicts sensitivity to alkylating agents, we hypothesized that Ki67 expression could also serve as a predictor of sensitivity to platinum salts and PARPi.


MITO 37 is a multicentre retrospective Italian study aiming at correlating Ki67 expression level with clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from all pts with high grade serous or endometroid BRCA WT OC treated with niraparib or rucaparib maintenance between 2010-2021. Ki67 expression was assessed by certified pathologists on formalin-fixed paraffin embedded tumor at diagnosis and at relapse (if available) before PARPi.


131 pts from 14 centres were included. Most pts were serous OC (93%, 121/131), advanced-stage (81%, 106/131 FIGO stage III-IV). The majority (71%, 93/131) had absence of residual disease (R0) at primary surgery. Median platinum free interval (PFI) at first relapse was 22.5 months (IQR 12-25.5) and median number of lines before PARPi was 2 (range 1-5). Niraparib was the most used PARPi (89%, 117/131). Best response to PARPi was: 30% (38/126) complete response (CR), 25% (31/126) partial response (PR), 21% (27/126) stable disease, 24% (27/126) progressive disease. Ki-67 was available for 129 pts at diagnosis and 22 at relapse. At diagnosis, median Ki67 was 49% (IQR 25%-70%). Higher Ki67 (using median as cut-off) was significantly associated with higher rate of R0 at surgery (100% vs 54.8%, p<0.001), longer first PFI (median 18.8 vs 27.2 months, p=0.03) and higher response to PARPi (71% vs 28% CR+PR, p<0.005). Similar results were observed using 75th percentile as Ki67 cut-off.


Preliminary results show that high Ki-67 at diagnosis potentially discriminates among BRCA WT responders to PARPi. Further analyses are ongoing.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.